Bright Minds Biosciences to Present at Upcoming Conferences

Rhea-AI Summary

Bright Minds Biosciences (NASDAQ: DRUG) will present at two investor conferences in November 2025: the Jefferies Global Healthcare Conference in London on November 10, 2025 at 12:00pm GMT (7:00am ET) and the Guggenheim 2nd Annual Healthcare Innovation Conference on November 12, 2025 at 9:00am ET.

The Guggenheim presentation will be available live and archived via webcast; a replay will be accessible from the company website for 60 days. There is no webcast for the Jefferies event. In addition, the company granted stock options to certain directors, officers and consultants to purchase an aggregate 43,000 common shares at an exercise price of US$54.47 per share, exercisable for five years and subject to vesting over the option term.

NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Bright Minds Biosciences, Inc. (“Bright Minds,” “BMB” or the “Company”) (NASDAQ: DRUG), a pioneering company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders, today announced that the Company will present at the following upcoming conferences:

	EVENT:	Guggenheim 2nd Annual Healthcare Innovation Conference
	DATE:	Wednesday, November 12, 2025
	TIME:	9:00am ET
	WEBCAST:	https://event.summitcast.com/view/6h3HS7z68WnTQE5PS7Vq8J/F9hC9xPJYgD5EJwoHF3vGF
	EVENT:	Jefferies Global Healthcare Conference in London
	DATE:	Monday, November 10, 2025
	TIME:	12pm GMT / 7am ET
	WEBCAST:	There is no webcast for this event

The live and archived webcast for the Guggenheim event will be accessible from the Company’s website at https://brightmindsbio.com/investors/ under Events and Presentation. The replay of the webcast will be accessible for 60 days.

Grant of Equity Incentive Awards

The Company has granted stock options (the “Options”) to certain directors, officers and consultants of the Company to purchase an aggregate 43,000 common shares (the “Shares”) in the capital of the Company pursuant to the Company’s share option plan. The Options are exercisable at an exercise price of US$54.47 per Share for a period of five (5) years from the date of grant. The Options are subject to vesting periods over the course of the term of the Options.

About Bright Minds Biosciences

Bright Minds Biosciences is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds Biosciences has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Investor Relations
Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com
Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com
Website: www.brightmindsbio.com

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.
The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

FAQ

When will Bright Minds Biosciences (DRUG) present at the Jefferies Global Healthcare Conference?

Bright Minds will present on November 10, 2025 at 12:00pm GMT / 7:00am ET; there is no webcast for this event.

How can investors watch Bright Minds (DRUG) at the Guggenheim Healthcare Innovation Conference?

The Guggenheim presentation will be webcast live and archived; the replay is available on the company investor site for 60 days.

Where is the Bright Minds (DRUG) Guggenheim webcast hosted?

The live and archived Guggenheim webcast is accessible from the company investor events page at https://brightmindsbio.com/investors/.

What equity awards did Bright Minds (DRUG) grant on October 30, 2025?

The company granted options to purchase an aggregate 43,000 common shares to certain directors, officers and consultants.

What are the terms of the stock options granted by Bright Minds (DRUG)?

Options are exercisable at US$54.47 per share for five years from the grant date and are subject to vesting over the option term.

Will the Bright Minds (DRUG) Guggenheim webcast be archived for later viewing?

Yes; the replay will be accessible on the company investor site for 60 days after the event.